Association between the N-terminal plasma brain natriuretic peptide levels or elevated left ventricular filling pressure and thromboembolic risk in patients with non-valvular atrial fibrillation

Yu, Ga-In; Cho, Kyoung-Im; Kim, Hyun-Su; Heo, Jung-Ho; Cha, Tae-Joon

doi:10.1016/j.jjcc.2015.11.015

Cited by 9 publications

(7 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given that shear stress correlates directly with blood velocity and inversely with chamber diameter (2), increased LA size as a result of severe and long-standing MR may be an exacerbating factor of LA SEC. Moreover, severe MR can often be associated with heart failure, which is identified as a prothrombotic state (31).…”

Section: La Sec and Mitral Regurgitationmentioning

confidence: 99%

Left atrial spontaneous echo contrast: relationship with clinical and echocardiographic parameters

Ito

Suwa

2019

Echo Res Pract

View full text Add to dashboard Cite

Spontaneous echo contrast (SEC) indicates blood stasis in cardiac chambers and major vessels, and is a known precursor of thrombus formation. Transesophageal echocardiography plays a pivotal role in detecting and grading SEC in the left atrial (LA) cavity. Assessing LA SEC can identify patients at increased risk for thromboembolic events. LA SEC also develops in patients who have sinus rhythm, especially in those with heart failure. Detection of LA SEC is not uncommon in subjects who have multiple cardiovascular comorbidities, although mechanisms behind this association are not fully understood. In patients with atrial fibrillation, the role of mitral regurgitation in counteracting LA SEC and subsequent thromboembolism is controversial. Moreover, alterations of blood coagulability and elevated levels of certain biological markers in the blood contribute to occurrence of LA SEC. This review describes the pathogenesis and assessment of SEC, in addition to the relationship between LA SEC and clinical, biological and echocardiographic parameters.

show abstract

Section: La Sec and Mitral Regurgitationmentioning

confidence: 99%

Left atrial spontaneous echo contrast: relationship with clinical and echocardiographic parameters

Ito

Suwa

2019

Echo Res Pract

View full text Add to dashboard Cite

show abstract

“…While freedom from AF is a binary outcome useful for research [21,22], the real world may be more forgiving of a low burden of AF or infrequent recurrences that may still be associated with a good clinical outcome. Since AF recurrence is currently defined as an episode lasting >30 s [8], the single procedure AF freedom without AADs was limited.…”

Section: Role Of Af Ablation In the Management Of Afmentioning

confidence: 99%

Impact of catheter ablation of atrial fibrillation on long-term clinical outcomes in patients with heart failure

Ichijo

Miyazaki

Kusa

et al. 2018

Journal of Cardiology

View full text Add to dashboard Cite

show abstract

“…NT-proBNP is a cardiac biomarker indicative of cardiac wall stress and levels increase when heart ventricles become overloaded. NT-proBNP levels are used to diagnose congestive heart failure [ 5 , 11 , 12 , 13 , 14 ]. In contrast, cTnT-HS, as a biomarker, specifically detects myocardial damage [ 15 , 16 ].…”

Section: Discussionmentioning

confidence: 99%

Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatment

Oghina

Josse²,

Bézard

et al. 2021

JCM

View full text Add to dashboard Cite

Background: We assesse the evolution and prognostic value of N-terminal pro-brain natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (cTnT-HS) in transthyretin amyloid cardiomyopathy (ATTR-CA) before and after tafamidis treatment. Methods and Results: 454 ATTR-CA patients without tafamidis (Cohort A) and 248 ATTR-CA with tafamidis (Cohort B) were enrolled. Event-free survival (EFS) events were death, heart transplant, or acute heart failure. In Cohort A, 27% of patients maintained NT-proBNP < 3000 ng/L and 14% cTnT-HS < 50 ng/L at 12 months relative to baseline levels. In Cohort B, the proportions were 49% and 29%, respectively. In Cohort A, among the 333 patients without an increased NT-proBNP > 50% relative to baseline EFS was extended compared to the 121 patients with an increased NT-proBNP > 50% (HR: 0.75 [0.57; 0.98]; p = 0.032). In Cohort A, baseline NT-proBNP > 3000 ng/L and cTnT-HS > 50 ng/L and a relative increase of NT-proBNP > 50% during follow-up were independent prognostic factors of EFS. The slopes of logs NT-proBNP and cTnT-HS increased with time before and stabilized after tafamidis. Conclusion: ATTR-CA patients with increasing NT-proBNP had an increased risk of EFS. Tafamidis stabilize NT-proBNP and cTnT-HS increasing, even if initial NT-proBNP levels were >3000 ng/L. Thus suggesting that all patients, irrespective of baseline NT-proBNP levels, may benefit from tafamidis.

show abstract

Association between the N-terminal plasma brain natriuretic peptide levels or elevated left ventricular filling pressure and thromboembolic risk in patients with non-valvular atrial fibrillation

Abstract: Elevated plasma NT-proBNP concentrations and LV filling pressures represented by LAA dysfunction may be reliable surrogate markers for predicting thromboembolic risk in patients with AF.

Cited by 9 publications

References 36 publications

Left atrial spontaneous echo contrast: relationship with clinical and echocardiographic parameters

Left atrial spontaneous echo contrast: relationship with clinical and echocardiographic parameters

Impact of catheter ablation of atrial fibrillation on long-term clinical outcomes in patients with heart failure

Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatment

Contact Info

Product

Resources

About